

PROGRAM

XI INTERNATIONAL CONFERENCE ON NOVEL PSYCHOACTIVE SUBSTANCES

Chaired by Prs.
Ornella Corazza
Olivier Rabin
Amine Benyamina
Faredj Cherikh

INSCRIPTION



Gala

Evening of 3 november
Cocktail reception, 20:00
Palais des Rois Sardes

Obligatory registration
Limited to 100 participants



3 & 4
NOVEMBER
2025

NICE
CENTRE UNIVERSITAIRE
MÉDITERRANÉEN



PROGRAM NPS 2025

Monday 3th / Tuesday 4, November 2025

EDUCATIONAL SHEET

LEARNING OBJECTIVES

- Examine global NPS trends and impacts
- Address challenges in detection and monitoring
- Foster international collaboration and knowledge exchange
- Strengthen public health responses to NPS

METHODS

- Keynote presentations
- Oral presentations
- Panel discussion
- Poster presentations
- Social events
- Networking sessions

No pre-requisites

TIME

- Monday 3th November 2025 : 08:30 - 19:00
- Tuesday 4, November 2025 : 08:30 - 11:30

AUDIENCE

The conference is intended for professionals and academics involved in research, public health, policy, law enforcement, and clinical practice related to NPS

SATISFACTION SURVEY

Satisfaction questionnaire

SCIENTIFIC COMMITTEE

Pr. Ornella Corazza

Professor in Addiction Science University of Hertfordshire (UH, United Kingdom) and University of Trento (Italy)

Pr. Olivier Rabin

Senior Director Science and Medicine at World Anti-Doping Agency (WADA) Montreal, Canada

Pr. Amine Benyamina

PU-PH Addictology psychiatrist President of the F.F.A. Head of Psychiatry and Addictology Hospital Paul-Brousse, Villejuif, France

Pr. Faredj Cherikh

PH en Psychiatry, Addictologist Head of the Addictology department CHU of Nice - CSAPA, France



PROGRAM NPS 2025

Monday 3th / Tuesday 4, November 2025

SPEAKERS

- Dr. Vincenzo Abbate**
Reader in Bioanalysis, King's College, United Kingdom
- Dr. Sophia Achab**
Clinical Director ReConnecte-HUG, Head WHO CC SWIS4 UNIGE, Switzerland
- Dr. Gil Artyom**
World Health Organization, Kazakhstan
- Ms. Vittoria Barbati**
Clinical Psychologist, Doctoral Researcher, University of Trento, Italy
- M. Michel Batten**
Kaleidoscope project, United Kingdom
- Pr. Amine Benyamina**
PU-PH Addictology psychiatrist, President of the F.F.A. Head of Psychiatry and Addictology, Hospital Paul-Brousse, Villejuif, France
- Pr. Giuseppe Bersani**
Psychiatrist specializing in clinical criminology and forensic psychiatry, Sapienza University, Italy
- Dr. Sabrina Bilei**
Researcher at University of Ferrara, Italy
- Ms. Stefania Bocuzzi**
PhD Researcher at King's College London, United Kingdom
- Mr. Jared Brown**
Scientific Affairs Officer at UNODC, Austria
- Dr. Julius Burkauskas**
Clinical Psychologist, Psychotherapist, Lithuanian University of Health Sciences (LSMU), Lithuania
- Ms. Anja Busse**
Unit Head, Drugs, Alcohol and Addictive Behaviours, World Health Organization (WHO), Geneva, Switzerland
- Mr. Alessandro Carollo**
Doctoral Researcher, University of Trento, Italy
- Mr. Riccardo Cavallaro**
Doctoral Researcher, University of Trento, Italy
- Pr. Faredj Cherikh**
Phen Psychiatry, Addictologist, Head of the Addictology department, CHU of Nice, CSAPA, France
- Dr. Caroline Copeland**
Senior Lecturer, Kings College London, Director of the National Program on Substance use mortality, United Kingdom
- Pr. Ornella Corazza**
Professor in Addiction Science University of Hertfordshire (UH, United Kingdom) and University of Trento (Italy)
- Pr. Christina Dalla**
Professor of Pharmacology at the University of Athens, Greece
- Mr. Ladislav Dékány**
Addictologist, Doctoral Researcher at Charles University, Czech Republic
- Dr. Francesco Di Carlo**
University of Chieti-Pescara, Italy
- Dr. David Erritzoe**
Clinical Director in Centre for Psychedelic Research, Imperial College London, United Kingdom
- Pr. Gianluca Esposito**
Director of the Department of Psychology and Cognitive Sciences, University of Trento, Italy
- Dr. Dimitra Florou**
Post-Doctoral Researcher at University of Ioannina, Greece
- Dr. Hironobu Fujiwara**
Psychiatrist, Assoc. Professor, Kyoto University, Japan
- Dr. Ana Gallegos**
Head of Early warning, alerts and laboratory network sector at European Union Drugs Agency (EUDA), Lisbon, Portugal
- Dr. Marie-Line Gilbert**
Senior Analyst, Researcher (Epidemiologist) Health Canada, Drug Analysis Service and Cannabis Laboratories, Canada
- Dr. Mariia Gofenberg**
Specialist of the Chemical Toxicological Laboratory, Sverdlovsk Regional Poison Treatment Centre, Sverdlovsk Regional Clinical Psychiatric Hospital, Russia
- Ms. Neshalatha Govarthnapanay**
ISSED, Pharmacist, Doctoral Researcher at Charles University, Czech Republic, University of Trento, Italy
- Dr. Claude Guillou**
Invited Scientific Expert, Italy
- Ms. Gabriella Hamú Giudice**
Early Warning System Specialist, Centre for Studies on Drugs and Community Social Development (Cdesc), UNODC, Brazil
- Pr. Zurina Hassan**
Deputy Director of Centre for Drug Research at Universiti Sains Malaysia, Malaysia
- Pr. Paul Hofman**
Director IHU RespirERA, IHU Côte d'Azur, Nice, France
- Dr. Joseph O. Ike**
Director General, Kaduna State Bureau of substance abuse (KADBUSA), Nigeria
- Ms. Olivia Johnson**
Forensic Senior Scientist - Drug Chemistry, The Institute of Environmental Science and Research (ESR), New Zealand
- M. Yerbotka Kassymov**
ISSED, University of Trento, Italy
- Dr. Merve Kuloğlu Genç**
Assistant Professor at İstanbul University-Cerrahpaşa Institute of Forensic Sciences and Legal Medicine, Turkey
- Ms. Clémence Lacroix**
Pharmacist, CEIP Addictovigilance Marseille APHM, France
- Pr. Lambros Lazuras**
Professor in Psychology, Sport and Exercise Science, University of Lincoln, United Kingdom
- Dr. Lisa Lione**
Assoc. Professor at University of Hertfordshire, United Kingdom
- Dr. Ilaria de Luca**
University of Hertfordshire, United Kingdom
- Dr. Irene Mazzoni**
Associate Director, Prohibited List, World Anti-Doping Agency, Canada
- Dr. Antonio Metastasio**
Consultant Psychiatrist, Camden and Islington NHS Trust, Italy
- Dr. Vidya Mohamed Ali**
Scientific Advisor at Anti-Doping Lab Qatar, United Kingdom
- Dr. Rama Mohamed Kamal**
Senior Consultant Addiction Psychiatrist Director Research and Education, Naufar, Qatar
- Mrs. Josephine Moore**
Substance misuse nurse manager at Kaleidoscope project, United Kingdom
- Ms. Renata de Moraes Souza**
Brazilian Health Regulatory Agency (Anvisa), Brazil
- Dr. Gabriele Penazzi**
Clinical Psychologist, Post-Doctoral Researcher, University of Trento, Italy
- Dr. Elisabeth Prevete**
Psychiatrist at the Psychiatry Unit of ASL Latina Hospital, Teacher of Psychiatry at the Degree Course in Nursing Sciences R of Sapienza University of Rome, Italy
- Dr. Mariya Prilutskaya**
Psychiatrist, Assoc. Professor at Semey Medical University, Kazakhstan
- Pr. Olivier Rabin**
Senior Director Science and Medicine at World Anti-Doping Agency (WADA), Montreal, Canada
- Pr. Tania Re**
UNESCO Chair in Anthropology of Health, Biosphere and Care Systems, University of Genoa, Italy
- Mr. Federico Seragnoli**
Doctoral Researcher at University of Lausanne, Switzerland
- Dr. Darshan Singh**
Assoc. Professor at University Sains Malaysia, Malaysia
- Dr. Eef Theunissen**
Assistant Professor at Maastricht University, Netherland
- Dr. Neha Tomar**
Assistant Professor at National Forensic Sciences University, India
- Ms. Sofia Venturini**
Doctoral Researcher at University of Hertfordshire, United Kingdom, University of Trento, Italy
- Dr. Guzalkhon Zakhidova**
Psychotherapist, Uzbekistan
- Dr. Thomas Zandonai**
Researcher at University of Trento, Italy, Miguel Hernandez University of Elche, Spain

Institutional representatives

M. Richard Chemla
Deputy Mayor of Nice for Health, Environment, Well-being and Animal Protection, France

M. Charles Ange Ginésy
President of the Alpes-Maritimes Department, France

Ms. Auréa Cophignon
Regional councilor of the Provence-Alpes-Côte d'Azur Region, France

M. Romain Alexandre
Departmental Director ARS Alpes-Maritimes, France



PROGRAM NPS 2025

Monday 3th / Tuesday 4, November 2025



Monday 3th

Morning



Centre
Universitaire
Méditerranéen

07:30 - 08:30

Reception of participants, presentation of badges,
registration by QR Code and coffee reception

OPENING SESSION

08:30 - 09:00 French institutional representatives

Official representatives

R. Chemla

O. Corazza

C. Ange Ginésy

O. Rabin

A. Cophignon

A. Benyamina

R. Alexandre

F. Cherikh

SESSION 1

09:00 - 10:35 / Chairs: C. Guillou, M. Prilutskaya . Online Moderators: G. Penazzi, E. Prevete

The changing face of illicit drug markets: a focus on NPS monitoring

09:00 - 09:20	Keynote 1 – Forensic early warning: a future-ready strategy against global NPS threats	J. Brown
09:20 - 09:35	Canadian drug notification system on new and potentially harmful substances	M-L. Gilbert
09:35 - 09:50	Mapping the emergence of New Psychoactive Substances in Brazil (2019–2025): a national survey supporting the Brazilian early warning system	G. Hamú Giudice
09:50 - 10:05	Development of an Integrated Drug Early Advisory System (IDEAS) to collate drug-related data in Aotearoa New Zealand	O. Johnson
10:05 - 10:20	Monitoring the results of chemical-toxicological studies of New Psychoactive Substances in the Sverdlovsk Regional Center (2015–2025)	M. Gofenberg
10:20 - 10:35	Overview of the shifting drug market in Uzbekistan: a key transit zone between Afghan methamphetamine and Kazakhstani cathinones	G. Zakhidova
10:35 - 11:05	Break and networking / Visit to the posters and exhibitors	

All presentations in English will be translated into French via headphones.



PROGRAM NPS 2025

Monday 3th / Tuesday 4, November 2025

SESSION 2

11:05 - 12:50 / Chairs: O. Rabin, O. Corazza . Online Moderators: V. Barbati, N. Govarthnapanay

From enhancement to dependency: the rising tide of IPEDs and prescription drug misuse

11:05 - 11:25	Keynote 2 – Image and performance enhancing drugs and mental health	V. Mohamed Ali
11:25 - 11:40	GLP-1 Drugs in the evolving landscape of IPEDs in sport and exercise	L. Lazuras
11:40 - 11:55	Enhancing under pressure: risk profile of IPED users	J. Burkaukas
11:55 - 12:10	Emerging drug trends in Japan: possible benefits of exercise, budo, and mindfulness as prevention strategies	H. Fujiwara
12:10 - 12:25	Investigating the risks and protective factors for IPED use in Latin America: the Panama project	T. Zandonai
12:25 - 12:40	The 'Benadryl Challenge'. A new social media trend.	S. Venturini
12:40 - 12:50	Performance	
12:50 - 14:00	<i>Invitation for a lunch break</i>	



Monday 3th
Afternoon



Centre
Universitaire
Méditerranéen

SESSION 3

14:00 - 17:00 / Chairs: A. Benyamina, I. De Luca . Online Moderators: A. Carollo, F. Di Carlo

Risks, harms, clinical management and new trends

14:00 - 14:20	Keynote 3 – Public health responses to psychoactive substance use: a WHO Update	A. Busse
14:20 - 14:40	Keynote 4 – Interview : A lived experience with NPS	O. Corazza J. Moore M. Batten
14:40 - 14:55	Clinical presentation of synthetic cannabinoid use: a case series from a middle eastern rehabilitation facility	R. Mohamed Kamal
14:55 - 15:10	Synthetic cathinone: the case of 3-Methylmethcathinone (3-MMC)	E. Theunissen

All presentations in English will be translated into French via headphones.



PROGRAM NPS 2025

Monday 3th / Tuesday 4, November 2025



15:10 - 15:25	From traditional use to dependence: investigating the neurobiological impact of kratom and mitragynine	Z. Hassan
15:25 - 15:40	Akuskura : an emerging psychoactive challenge in Nigeria	J. O. Ike
15:40 - 15:55	Investigating naloxone's efficacy in reversing cardiorespiratory effects of Novel Synthetic Opioids	S. Bilel
15:55 - 16:10	The kratom market and kratom products in the Czech Republic – Online Survey	L. Dékány
16:10 - 16:25	New drugs, new psychosis	G. Bersani
16:25 - 17:00	Panel discussion / Questions and answers Chair: A. Benyamina	I. Mazzoni F. Cherikh P. Hofman M. Prilutskaya C. Lacroix A. Metastasio
17:00 - 17:30	Coffee break and networking / Visit to the posters and exhibitors	
SESSION 4		
17:30 - 19:00 / Chairs: V. Abbate, O. Johnson . Online Moderators: R. Cavallaro, Y. Kassymov <i>Innovations in drug detection: from biological matrices to wastewater analysis</i>		
17:30 - 17:50	Keynote 5 – NPS in Europe: a perspective from the EU early warning system	A. Gallegos
17:50 - 18:05	Addiction and respiratory pathologies (local session)	P. Hofman
18:05 - 18:20	Responding to shifts in regional drug markets: LC-MS/MS method development for synthetic opioids in wastewater	M. Kuloğlu Genç
18:20 - 18:35	Streamlining analysis to inform management of acute recreational drug toxicity: advances in paper spray ionisation for rapid drug detection	S. Bocuzzi
18:35 - 18:50	Significance of conventional and alternative biological matrices in evaluating the extent of use of New Psychoactive Substances (NPS)	D. Florou
18:50 - 19:00	Closing remarks	G. Esposito

All presentations in English will be translated into French via headphones.



PROGRAM NPS 2025

Monday 3th / Tuesday 4, November 2025



Tuesday 4

Morning



Centre
Universitaire
Méditerranéen

07:30 - 08:30

Reception of participants, presentation of badges,
registration by QR Code and coffee reception.

SESSION 5

08:30 - 11:30 / Chair: M. Prilutskaya, E. Prevete . Online Moderators: G. Penazzi, I. De Luca

Global drug policy: challenges, trends, and harm reduction

08:30 - 08:50	Keynote 6 – Impact of punitive drug policies on harm reduction interventions	D. Singh Z. Hassan
08:50 - 09:20	Panel discussion: Public health and policy approaches to New Psychoactive Substances Chair: S. Achab	G. Artyom S. Renata de Morais C. Copeland A. Busse
09:20 - 09:50	Panel discussion: International society of emerging drugs and the new early career network Chair: O. Corazza	S. Venturini O. Rabin N. Govarthnapanay
<i>Break and networking / Visit to the posters and exhibitors</i>		
10:20 - 10:50	Panel discussion: Are psychedelics the next frontier in mental health care? Chair: C. Dalla	D. Erritzoe L. Lione F. Seragnoli G. Bersani T. Re
10:50 - 11:20	Closing panel discussion Chair: G. Esposito	C. Guillou O. Rabin A. Benyamina M. Prilutskaya V. Abbate S. Achab C. Dalla O. Corazza
11:20 - 11:30	Closing remarks	

All presentations in English will be translated into French via headphones.



PROGRAM NPS 2025

Monday 3th / Tuesday 4, November 2025

Target groups and structures

PRIVATE SECTOR, PUBLIC SECTOR AND MOBILE TEAMS

Addictology	General medicine
Allergology	Intensive care medicine
Anatomy and cytopathology	Internal medicine
Anaesthesia and intensive care	Nuclear medicine
Medical biology	Physical and rehabilitation medicine
Cardiovascular HTA	Vascular medicine
Surgery	Nephrology
Dentistry	Neurology
Dermatology and venereology	Nutrition
Endocrinology-diabetology-nutrition	Oncology
Medical genetics	Ophthalmology
Geriatrics	ENT
Medical gynaecology	Paediatrics
Haematology	Pharmacy
Hepato-gastro-enterology	Pneumology
Immunology	Psychiatry
Infectiology	Radiology and medical imaging
Cardiovascular medicine	Rheumatology
Emergency medicine	Public health
Sports medicine	Sexology
Occupational medicine	Toxicology
Medicine in prisons	Urology

Partners

EXHIBITORS AND SPONSORS



STRATEGY

- Creates events
- Facilitates communication
- Organises exchanges
- Has been in existence for over 15 years

Responsibilities:

- Contribute to the maintenance and development of knowledge
- Enhance the skills of professionals

Objectives:

- Contribute to improving the quality of professional practices
- Meet the expectations of management and administrative teams in terms of management

ACTIVITY

Organisation of trade fairs, conferences and seminars.
Facilitation of internal and external training sessions.

CONTACT

CLEF : Centre de Liaison, d'Études et de Formation

-  6 avenue Henri Barbusse, Immeuble l'Astragale, 06100 Nice
-  +33(0) 493 183 360 / Fax : 04 93 17 60 82
-  formation@le-clef.fr
-  www.le-clef.fr